Results 221 to 230 of about 48,467 (263)
Successful Multimodal Therapeutic Approach for CD30‐positive Folliculotropic Mycosis Fungoides
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page e1123-e1125, August 2026.
Chiara L. Blomen +5 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Critical Reviews in Oncology/Hematology, 2008
Follicular lymphomas constitute approximately 30% of all non-Hodgkin lymphomas. These lymphomas are characterized by at least partially follicular growth pattern, but diffuse areas may be present. The proportions of follicular or diffuse areas vary also from case to case, which seems to be associated with prognosis.
Umberto, Vitolo +2 more
openaire +2 more sources
Follicular lymphomas constitute approximately 30% of all non-Hodgkin lymphomas. These lymphomas are characterized by at least partially follicular growth pattern, but diffuse areas may be present. The proportions of follicular or diffuse areas vary also from case to case, which seems to be associated with prognosis.
Umberto, Vitolo +2 more
openaire +2 more sources
Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma.
Blood, 2012Abstract Abstract 2648 Follicular lymphoma (FL) is an indolent lymphoma and the second most common type of non-Hodgkin lymphoma in the Western world. It is characterized by the t(14;18) chromosomal translocation, which is present in up to 90% of cases.
Wright, George W +22 more
openaire +2 more sources
Treatment of follicular lymphoma
Current Opinion in Oncology, 1998Follicular lymphoma is one of the most common neoplastic lymphoproliferative diseases encountered in the western world. Intensive scientific scrutiny has led to detailed understanding of the nature of the malignant cell and the specific genetic abnormalities which are frequently encountered and likely to be etiologic.
J M, Connors, R, Klasa
openaire +2 more sources
Obinutuzumab in follicular lymphoma
Drugs of Today, 2016The CD20 marker continues to be exploited as a therapeutic target for non-Hodgkin's lymphoma. Obinutuzumab is part of a new generation of anti-CD20 monoclonal antibodies, which are synthesized using molecular engineering technology, resulting in novel target epitopes and unprecedented optimization of antibody-dependent cellular cytotoxicity and ...
Martinez-Calle, N. (Nicolas) +4 more
openaire +3 more sources
Hematological Oncology, 2023
AbstractThe past two decades have seen remarkable progress in both biological understanding and optimizing treatment of follicular lymphoma. Historically considered an incurable disease, long‐term follow‐up of several induction approaches demonstrates that up to 40% of patients enjoy remission durations of 10 or more years, and risk of dying of ...
openaire +2 more sources
AbstractThe past two decades have seen remarkable progress in both biological understanding and optimizing treatment of follicular lymphoma. Historically considered an incurable disease, long‐term follow‐up of several induction approaches demonstrates that up to 40% of patients enjoy remission durations of 10 or more years, and risk of dying of ...
openaire +2 more sources
2021
Follicular lymphoma (FL) is an indolent yet challenging disease. Despite a generally favorable response to immunochemotherapy regimens, a fraction of patients does not respond or relapses early with unfavorable prognosis. For the vast majority of those who initially respond, relapses will repeatedly occur with increasing refractoriness to available ...
Milpied, Pierre +6 more
openaire +3 more sources
Follicular lymphoma (FL) is an indolent yet challenging disease. Despite a generally favorable response to immunochemotherapy regimens, a fraction of patients does not respond or relapses early with unfavorable prognosis. For the vast majority of those who initially respond, relapses will repeatedly occur with increasing refractoriness to available ...
Milpied, Pierre +6 more
openaire +3 more sources
Radioimmunotherapy in follicular lymphoma
Best Practice & Research Clinical Haematology, 2011The exquisite sensitivity of haematological malignancies to targeted radiation make Radioimmunotherapy (RIT) a theoretically attractive therapeutic approach. Furthermore, impressive results initially achieved by the pioneers in this field and more recently in larger studies have demonstrated the high clinical activity of RIT in follicular NHL (FL). For
Illidge, Tim; id_orcid 0000-0003-3191-7324 +1 more
openaire +3 more sources
Prognosis of follicular lymphomas
Hematological Oncology, 2006AbstractFollicular lymphoma (FL) is as an indolent neoplasia with median survival measured in decades. Nevertheless, some patients have poor progression‐free survival and overall survival. Several treatment approaches are proposed for patients with FL, however criteria to rationalize treatment decisions are lacking. Studies have been performed to build
LUMINARI, Stefano, FEDERICO, Massimo
openaire +2 more sources